Biotech startups that raised Series A in California, United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Zafrens | San Diego | Series A | $6.0M | 2026-11-03 |
| Probably Genetic | San Francisco | Series A | $12.0M | 2026-10-15 |
| ImpriMed | Palo Alto | Series A | $10.0M | 2026-09-18 |
| Mithrl | San Francisco | Series A | $20.0M | 2026-09-15 |
| TwoStep Therapeutics | Palo Alto | Series A | $62.5M | 2026-09-09 |
| Integrated Biosciences | Redwood City | Series A | $68.4M | 2026-08-05 |
| Transcripta Bio | Palo Alto | Series A | $24.0M | 2026-07-22 |
| Condor Software | San Diego | Series A | $24.0M | 2026-03-18 |
8 rows of the CSV in 5 of its 18 columns.
- The 366 biotech startups in California, United States whose last round is Series A have raised $17.3B in total.
- 47 of them closed their most recent round in the last 12 months, $2.3B combined.
- The largest of those rounds is Warp Sciences' $215.0M Series A, dated October 2026.
- The most recent is Zafrens' $6.0M Series A on 3 November 2026.
- Plug and Play is an investor in 5 of them, more than any other fund.
- Health care is the most common other sector, with 306 companies (84%).
- 29% were founded in 2020 or later; the median founding year is 2017.
- The most common team size is 11 to 50 employees (61% of companies with a recorded size).
- 1 is a unicorn, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 366| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Zafrens | Zafrens provides a throughput platform that links molecular profiles to cell phenotypes for drug discovery. | Biotech | San Diego | Series A | $6.0M | 2026-11-03 | $35.0M | Liquid 2 Ventures, Global Brain Corporation, BlueYard Capital +2 | 11 to 50 | 2022 |
| Probably Genetic | Probably Genetic develops treatments aimed at improving the lives of patients with severe, complex diseases. | Artificial intelligence | San Francisco | Series A | $12.0M | 2026-10-15 | $22.9M | Y Combinator, Khosla Ventures, TenOneTen Ventures +2 | 11 to 50 | 2018 |
| ImpriMed | ImpriMed provides AI-driven precision medicine services to oncologists and pharmaceutical companies. | Artificial intelligence | Palo Alto | Series A | $10.0M | 2026-09-18 | $44.7M | Plug and Play, Pear VC, Draper Associates +1 | 51 to 100 | 2017 |
| Mithrl | Mithrl is a software development company that builds custom NGS data workflows on demand. | Artificial intelligence | San Francisco | Series A | $20.0M | 2026-09-15 | $24.0M | Bonfire Ventures | 51 to 100 | 2023 |
| TwoStep Therapeutics | TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. | Biotech | Palo Alto | Series A | $62.5M | 2026-09-09 | $90.1M | NFX, 2048 Ventures, Alexandria Venture Investments +1 | 11 to 50 | 2023 |
| Integrated Biosciences | Integrated Bio develops multimodal biological datasets and AI for drug discovery against age-related diseases. | Artificial intelligence | Redwood City | Series A | $68.4M | 2026-08-05 | $85.6M | Root Ventures, Reinforced Ventures, Mission BioCapital +2 | 11 to 50 | 2022 |
| Transcripta Bio | Transcripta Bio develops drugs at an accelerated pace with reduced risk. | Biotech | Palo Alto | Series A | $24.0M | 2026-07-22 | $34.4M | BlueYard Capital, Jazz Venture Partners | 11 to 50 | 2020 |
| Condor Software | Condor Software is a financial intelligence platform that connects clinical, operational, and financial data in real time. | Biotech | San Diego | Series A | $24.0M | 2026-03-18 | $29.5M | Plug and Play, MassChallenge, Pareto Holdings +1 | 11 to 50 | 2020 |
| Medra AI | Medra AI builds an autonomous scientific experimentation platform that combines robotics with artificial intelligence. | Artificial intelligence | San Francisco | Series A | $52.0M | 2025-12-11 | $63.0M | PharmStars | 11 to 50 | 2021 |
| Perelel | Perelel makes supplements designed for different stages of a woman's reproductive life cycle. | Biotech | Los Angeles | Series A | $27.0M | 2025-11-20 | $41.7M | Unilever Ventures, Willow Growth Partners, Selva Ventures | 11 to 50 | 2018 |
| Mosanna Therapeutics | Mosanna Therapeutics develops a nasal spray for treating obstructive sleep apnea. | Biotech | Redwood City | Series A | $80.0M | 2025-06-09 | $80.0M | HTGF (High-Tech Gruenderfonds), Supermoon Capital | 1 to 10 | 2022 |
| Persist AI | Persist AI is a biotechnology company that develops long-acting microsphere drug formulations. | Artificial intelligence | Woodland | Series A | $12.0M | 2025-03-19 | $16.5M | Y Combinator, Pioneer Fund, 2048 Ventures +2 | 11 to 50 | 2022 |
| Trace Neuroscience | Trace Neuroscience aims to extend the promise of genetic medicine to patients. | Biotech | South San Francisco | Series A | $101.0M | 2024-11-12 | $101.0M | RA Capital Management, Atlas Venture, Third Rock Ventures | 11 to 50 | 2024 |
| Oloid | Oloid provides passwordless access for frontline workers and shared devices. | Biotech | Sunnyvale | Series A | $6.0M | 2024-10-24 | $23.0M | Plug and Play, Unusual Ventures, WestWave Capital +2 | 51 to 100 | 2019 |
| MiLaboratories | MiLaboratories is a biotech company that develops software for immune repertoire profiling. | Biotech | Sunnyvale | Series A | $10.0M | 2024-10-10 | $12.4M | Speedinvest, K Fund, Acrobator Ventures +2 | 11 to 50 | 2021 |
| Shinobi Therapeutics | Shinobi Therapeutics develops immune-evasive iPS cell therapies for cancer treatment. | Biotech | South San Francisco | Series A | $68.0M | 2024-08-06 | $178.0M | Mitsubishi UFJ Capital, F-Prime, EQT Life Sciences +2 | 11 to 50 | 2023 |
| NGM Biopharmaceuticals | NGM Biopharmaceuticals discovers and develops biotherapeutics for gastrointestinal and endocrine disorders. | Biotech | South San Francisco | Series A | $122.0M | 2024-07-17 | $542.4M | Rho Capital Partners, Greenspring Associates, The Column Group | 11 to 50 | 2008 |
| Digestiva | Digestiva develops food and feed proteins with improved nutritional and sensory properties using targeted biocatalysts. | Biotech | Sacramento | Series A | $18.4M | 2024-07-15 | $18.4M | Astanor Ventures, UC Investments | 11 to 50 | 2018 |
| Immunis | Immunis is a private biotechnology company developing a treatment for age and disease-related immune decline. | Biotech | Irvine | Series A | $25.0M | 2024-07-01 | $35.0M | Healthspan Capital, Remiges Ventures, Continuum Health Ventures | 11 to 50 | 2018 |
| Raydiant Oximetry | Raydiant Oximetry makes medical devices that improve outcomes for mothers and babies during childbirth. | Biotech | San Ramon | Series A | $7.5M | 2024-06-04 | $25.6M | National Science Foundation, Enterprise Ireland, National Institutes of Health +1 | 11 to 50 | 2016 |
| Xaira Therapeutics Unicorn | Xaira Therapeutics applies artificial intelligence to drug discovery and biotechnology research. | Artificial intelligence | South San Francisco | Series A | $1.0B | 2024-04-23 | $1.0B | Sequoia Capital, New Enterprise Associates, Menlo Ventures +2 | 101 to 250 | 2023 |
| Kryptos Biotechnologies | Kryptos Biotechnologies provides life science systems that reveal the complexity of biology for clinicians and scientists. | Biotech | Hayward | Series A | $10.0M | 2024-03-28 | $21.8M | SkyDeck Berkeley, FuturePlay, KDB Capital | 1 to 10 | 2017 |
| Argonaut Manufacturing Services | Argonaut Manufacturing Services provides contract manufacturing for biopharmaceutical, diagnostics, and life science organizations. | Biotech | Carlsbad | Series A | $45.0M | 2024-03-05 | $67.3M | Square 1 Bank, Telegraph Hill Partners, NewVale Capital | 51 to 100 | 2016 |
| CRISPR QC | CRISPR QC provides an analytics platform that delivers insights for biotechnology research. | Biotech | San Diego | Series A | $10.0M | 2024-01-04 | $12.5M | Serra Ventures, Xcellerant Ventures | 11 to 50 | 2021 |
| Kimia Therapeutics | Kimia is a drug discovery company that applies high throughput precision chemistry. | Biotech | Berkeley | Series A | $55.0M | 2023-12-19 | $55.0M | Horizons Ventures, The Column Group, Dimension Capital | 11 to 50 | 2022 |
| Cytonus Therapeutics | Cytonus Therapeutics develops novel therapeutics using its proprietary drug delivery platform. | Artificial intelligence | Carlsbad | Series A | $11.7M | 2023-11-03 | $20.9M | National Institutes of Health, Creative Ventures | 11 to 50 | 2018 |
| Aiolos Bio | Aiolos Bio is a biotech company developing therapies for respiratory diseases and immune conditions. | Biotech | San Francisco | Series A | $245.0M | 2023-10-24 | $245.0M | RA Capital Management, Atlas Venture, Forbion Capital Partners +2 | 11 to 50 | 2023 |
| Rampart Bioscience | Rampart Bioscience develops gene medicines for long-lasting treatment of diverse diseases. | Biotech | La Jolla | Series A | $85.0M | 2023-10-24 | $85.0M | RA Capital Management, OrbiMed, Forbion Capital Partners +1 | 11 to 50 | 2019 |
| Actym Therapeutics, Inc. | Actym Therapeutics discovers and develops novel immuno-oncology therapies to treat cancer. | Biotech | Berkeley | Series A | $25.5M | 2023-10-18 | $59.5M | Korea Investment Partners, Boehringer Ingelheim Venture Fund, Illumina Ventures +2 | 11 to 50 | 2017 |
| Pow.bio | Pow.bio provides genetically engineered microbes for fermentation scientists. | Biotech | Berkeley | Series A | $9.7M | 2023-10-04 | $11.5M | National Science Foundation, Climate Capital, Cantos +2 | 11 to 50 | 2019 |
Table 1. Biotech startups that raised Series A in California, United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 366.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Integrated Biosciences | Integrated Bio develops multimodal biological datasets and AI for drug discovery against age-related diseases. | Artificial intelligence | Redwood City | Series A | $68.4M | 2026-08-05 | $85.6M | Root Ventures, Reinforced Ventures, Mission BioCapital +2 | 11 to 50 | 2022 |
| 2 | TwoStep Therapeutics | TwoStep Therapeutics develops tumor-targeting therapeutics for solid tumors. | Biotech | Palo Alto | Series A | $62.5M | 2026-09-09 | $90.1M | NFX, 2048 Ventures, Alexandria Venture Investments +1 | 11 to 50 | 2023 |
| 3 | Medra AI | Medra AI builds an autonomous scientific experimentation platform that combines robotics with artificial intelligence. | Artificial intelligence | San Francisco | Series A | $52.0M | 2025-12-11 | $63.0M | PharmStars | 11 to 50 | 2021 |
| 4 | Perelel | Perelel makes supplements designed for different stages of a woman's reproductive life cycle. | Biotech | Los Angeles | Series A | $27.0M | 2025-11-20 | $41.7M | Unilever Ventures, Willow Growth Partners, Selva Ventures | 11 to 50 | 2018 |
| 5 | Transcripta Bio | Transcripta Bio develops drugs at an accelerated pace with reduced risk. | Biotech | Palo Alto | Series A | $24.0M | 2026-07-22 | $34.4M | BlueYard Capital, Jazz Venture Partners | 11 to 50 | 2020 |
| 6 | Condor Software | Condor Software is a financial intelligence platform that connects clinical, operational, and financial data in real time. | Biotech | San Diego | Series A | $24.0M | 2026-03-18 | $29.5M | Plug and Play, MassChallenge, Pareto Holdings +1 | 11 to 50 | 2020 |
| 7 | Mithrl | Mithrl is a software development company that builds custom NGS data workflows on demand. | Artificial intelligence | San Francisco | Series A | $20.0M | 2026-09-15 | $24.0M | Bonfire Ventures | 51 to 100 | 2023 |
| 8 | Probably Genetic | Probably Genetic develops treatments aimed at improving the lives of patients with severe, complex diseases. | Artificial intelligence | San Francisco | Series A | $12.0M | 2026-10-15 | $22.9M | Y Combinator, Khosla Ventures, TenOneTen Ventures +2 | 11 to 50 | 2018 |
| 9 | ImpriMed | ImpriMed provides AI-driven precision medicine services to oncologists and pharmaceutical companies. | Artificial intelligence | Palo Alto | Series A | $10.0M | 2026-09-18 | $44.7M | Plug and Play, Pear VC, Draper Associates +1 | 51 to 100 | 2017 |
| 10 | Zafrens | Zafrens provides a throughput platform that links molecular profiles to cell phenotypes for drug discovery. | Biotech | San Diego | Series A | $6.0M | 2026-11-03 | $35.0M | Liquid 2 Ventures, Global Brain Corporation, BlueYard Capital +2 | 11 to 50 | 2022 |
Table 2. Biotech startups that raised Series A in California, United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Plug and Play | Startup accelerator | Sunnyvale, United States | 5 | 1% | 2 | ImpriMed, Condor Software |
| 2 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 4 | 1% | ||
| 3 | Y Combinator | Startup accelerator | Mountain View, United States | 3 | 1% | 1 | Probably Genetic |
| 4 | Lux Capital | Venture capital firm | New York, United States | 3 | 1% | ||
| 5 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 3 | 1% | ||
| 6 | New Enterprise Associates | Venture capital firm | Menlo Park, United States | 3 | 1% | ||
| 7 | F-Prime | Venture capital firm | Cambridge, United States | 3 | 1% | ||
| 8 | RA Capital Management | Startup incubator | Boston, United States | 3 | 1% | ||
| 9 | S32 | Venture capital firm | San Diego, United States | 3 | 1% | ||
| 10 | BlueYard Capital | Venture capital firm | Berlin, Germany | 2 | 1% | 2 | Zafrens, Transcripta Bio |
| 11 | Liquid 2 Ventures | Venture capital firm | San Francisco, United States | 2 | 1% | 1 | Zafrens |
| 12 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 2 | 1% | 1 | Probably Genetic |
| 13 | 2048 Ventures | Venture capital firm | New York, United States | 2 | 1% | 1 | TwoStep Therapeutics |
| 14 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 2 | 1% | 1 | TwoStep Therapeutics |
| 15 | Jazz Venture Partners | Venture capital firm | San Francisco, United States | 2 | 1% | 1 | Transcripta Bio |
Table 3. Biotech startups that raised Series A in California, United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 306 | 84% | $15.8B |
| Software | 58 | 16% | $2.4B |
| Artificial intelligence | 36 | 10% | $2.1B |
| Hardware | 12 | 3% | $125.8M |
| Cybersecurity | 4 | 1% | $39.2M |
| Energy | 4 | 1% | $337.7M |
| Fintech | 3 | 1% | $48.7M |
| Commerce | 1 | 0% | $41.7M |
Table 4. Biotech startups that raised Series A in California, United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series A | 366 | 100% | $20.0M |
Table 5. Biotech startups that raised Series A in California, United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Francisco | 77 | 21% |
| San Diego | 62 | 17% |
| Palo Alto | 34 | 9% |
| South San Francisco | 19 | 5% |
| Menlo Park | 13 | 4% |
| Berkeley | 12 | 3% |
| Mountain View | 12 | 3% |
| San Mateo | 9 | 2% |
| Los Angeles | 9 | 2% |
| La Jolla | 8 | 2% |
| Irvine | 7 | 2% |
| Redwood City | 6 | 2% |
Table 6. Biotech startups that raised Series A in California, United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 2% | $6.0M |
| October 2026 | 6 | 13% | $454.1M |
| September 2026 | 5 | 11% | $186.5M |
| August 2026 | 3 | 6% | $155.9M |
| July 2026 | 3 | 6% | $48.3M |
| June 2026 | 5 | 11% | $123.4M |
| May 2026 | 4 | 9% | $246.9M |
| March 2026 | 6 | 13% | $119.4M |
| February 2026 | 3 | 6% | $97.8M |
| January 2026 | 3 | 6% | $349.0M |
| December 2025 | 6 | 13% | $408.6M |
| November 2025 | 2 | 4% | $147.0M |
Table 7. Biotech startups that raised Series A in California, United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 39 | 11% | $1.8B |
| 2025 | 44 | 12% | $2.4B |
| 2024 | 29 | 8% | $1.9B |
| 2023 | 34 | 9% | $1.1B |
| 2022 | 36 | 10% | $1.1B |
| 2021 | 38 | 10% | $4.0B |
Table 8. Biotech startups that raised Series A in California, United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 35 | 10% |
| 2020 to 2022 | 70 | 19% |
| 2015 to 2019 | 126 | 35% |
| 2010 to 2014 | 70 | 19% |
| Before 2010 | 63 | 17% |
Table 9. Biotech startups that raised Series A in California, United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 102 | 29% |
| 11 to 50 | 215 | 61% |
| 51 to 100 | 26 | 7% |
| 101 to 250 | 9 | 3% |
| 251 to 500 | 1 | 0% |
| 501 to 1,000 | 1 | 0% |
| 10,001 or more | 1 | 0% |
Table 10. Biotech startups that raised Series A in California, United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series A and its headquarters is in California, United States. On 16 November 2026 that is 366 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 366 rows: 39 have no round amount, 0 no city and 44 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in California, United States whose last round is Series A are on the list?
- 366, in the file dated 16 November 2026. 47 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 366 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.